Botanix Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BXPHF research report →
Companywww.botanixpharma.com
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis.
- CEO
- Howie McKibbon
- IPO
- 2019
- Employees
- 11
- HQ
- Leederville, WA, AU
Price Chart
Valuation
- Market Cap
- $41.84M
- P/E
- -0.55
- P/S
- 2.27
- P/B
- 0.91
- EV/EBITDA
- -0.59
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -118.23%
- Op Margin
- -380.62%
- Net Margin
- -404.72%
- ROE
- -131.13%
- ROIC
- -99.26%
Growth & Income
- Revenue
- $5.76M · 178.20%
- Net Income
- $-86,396,186 · -522.91%
- EPS
- $-0.05 · -408.70%
- Op Income
- $-86,342,852
- FCF YoY
- -204.80%
Performance & Tape
- 52W High
- $0.33
- 52W Low
- $0.01
- 50D MA
- $0.03
- 200D MA
- $0.07
- Beta
- 0.83
- Avg Volume
- 16.07K
Get TickerSpark's AI analysis on BXPHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BXPHF Coverage
We haven't published any research on BXPHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BXPHF Report →